Comparisons of SOX and FOLFOX6 chemotherapies on operative treatment of locally advanced gastric cancer

Abstract:

Objective：To compare differences of clinical efficacy，postoperative outcomes and survival between the oxaliplatin com－bined with tegafur（SOX） and the oxaliplatin combined with calcium folinate and fluorouracil（FOLFOX6） neoadjuvant chemotherapies in patients with locally advanced gastric cancer. Methods：From January 2012 to August 2013，data of 87 patients with locally ad－vanced gastric cancer underwent operation and received SOX and FOLFOX6 chemotherapies were retrospectively analyzed. According to chemotherapy scheme，these patients were divided into the observation group（SOX，n=45） and the control group（FOLFOX6，n=42）. Chemotherapeutic efficacy，adverse reactions，surgical conditions，postoperative outcomes，complications and survival conditions in two groups were compared. Results：There were no significant differences in chemotherapeutic efficacy，dissection rate of D2 lymph node，R0 dissection rate，incidence rate of postoperative complications and pathological tumor regression grade between two groups（P > 0.05）. There were no adverse reactions of Ⅲ-Ⅳ level in two groups. The incidence of nausea，vomiting and diarrhea（Ⅰ-Ⅱ level） during chemotherapy in the observation group was significantly lower than that in the control group（35.56% vs. 73.81%，χ2=12.799，P=0.000；6.67% vs. 30.95%， χ2=8.537，P=0.003）. The progression-free survival rate in the observation group at 1，3，5 years were 95.56%，55.56%，28.89%，respectively；those in the control group at 1，3，5 years were 92.86%，45.24%，23.81%，respectively，without statisti－cally significant differences（logrank χ2=0.474，P=0.491）. The cumulative survival rate in the observation group at 1，3，5 years were 97.78%，62.22%，31.11%，respectively；those in the control group at 1，3，5 years were 97.62%，50.00%，26.19%，respectively，without statistically significant differences（logrank χ2=0.666，P=0.414）. Conclusion：For treating the locally advanced gastric cancer，SOX has a similar efficacy FOLFOX6，but has amilder risk of gastrointestinal adverse reactions recommending for clinical use.